Evidence map›Paper›PMID 36979969›Full record

ReviewBiomedicines2023

Structure-Guided Prediction of the Functional Impact of DCLK1 Mutations on Tumorigenesis.

Annalisa L E Carli, Joshua M Hardy, Hanadi Hoblos, Matthias Ernst, Isabelle S Lucet, Michael Buchert

Open access · goldFull text readReview
In one paragraph

Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Annalisa L E CarliCancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0003-0312-1097
Joshua M HardyACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.ORCID 0000-0002-8014-8552
Hanadi HoblosACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Matthias ErnstCancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-6399-1177
Isabelle S LucetACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.ORCID 0000-0002-8563-8753
Michael BuchertCancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0003-2672-0148
La Trobe University · AUThe University of Melbourne · AU

Funding

LTU PhD scholarship (LTUFRS) N/ALTU RFA understanding disease grant N/ANational Health and Medical Research Council 1079257National Health and Medical Research Council 1092788National Health and Medical Research Council 1143020National Health and Medical Research Council 1162058National Health and Medical Research Council 1173814National Health and Medical Research Council 2008096WEHI Alan W Harris Scholarship N/A
6 · The paper itself

Abstract

Doublecortin-like kinase 1 (DCLK1) is a functional serine/threonine (S/T)-kinase and a member of the doublecortin family of proteins which are characterized by their ability to bind to microtubules (MTs). DCLK1 is a proposed cancer driver gene, and its upregulation is associated with poor overall survival in several solid cancer types. However, how DCLK1 associates with MTs and how its kinase function contributes to pro-tumorigenic processes is poorly understood. This review builds on structural models to propose not only the specific functions of the domains but also attempts to predict the impact of individual somatic missense mutations on DCLK1 functions. Somatic missense mutations in DCLK1 are most frequently located within the N-terminal MT binding region and likely impact on the ability of DCLK1 to bind to αβ-tubulin and to polymerize and stabilize MTs. Moreover, the MT binding affinity of DCLK1 is negatively regulated by its auto-phosphorylation, and therefore mutations that affect kinase activity are predicted to indirectly alter MT dynamics. The emerging picture portrays DCLK1 as an MT-associated protein whose interactions with tubulin heterodimers and MTs are tightly controlled processes which, when disrupted, may confer pro-tumorigenic properties.

Indexed as

cancercryo-EMcrystal structureDCLK1DCXdoublecortin domainkinasemicrotubulesmissense mutationsPEST domain

Identifiers

PMID36979969
PMCPMC10046695
OpenAlexW4360613899

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read28
table measurements read3
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.